https://www.gov.uk/government/publications/commissioning-of-public-health-services-for-children/early-years-high-impact-area-5-improving-health-literacy-managing-minor-illnesses-and-reducing-accidents<\/a><\/p>The Department is also working alongside NHS England and the National Child Mortality Database (NMCD) to increase the data bank on SIDS, to increase our evidence base, understanding, and inform actions and policy.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T17:41:19.253Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cot Deaths"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to raise awareness of what can be done to prevent Sudden Infant Death Syndrome.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "18448"}
, {"_about" : "http://data.parliament.uk/resources/1695751", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695751/answer", "answerText" : {"_value" : "
Adverse events of special interest (AESI) are medical events or conditions that have been identified as possible vaccine safety concerns, based mainly on previous experience with other vaccines and immune-mediated events which theoretically may occur, as vaccines stimulate an immune response. AESIs for COVID-19 vaccines were subject to enhanced surveillance by the Medicines and Healthcare products Regulatory Agency (MHRA) and many other regulators from the start of the United Kingdom\u2019s immunisation programme.<\/p>
Specifically in relation to AESIs, the MHRA has received 22880 UK spontaneous suspected adverse reaction (ADR) reports across all COVID-19 vaccines. Over 157 million doses of COVID-19 vaccines have been given in the UK. It is important to note that Yellow Card reports are not proof of a side effect occurring, and the incidence of a reaction occurring cannot be determined by these reports. The MHRA considers that the benefits of the COVID-19 vaccines continue to outweigh the risks for the majority of people.<\/p>
The MHRA acknowledges receipt of every Yellow Card report received, and a team of safety experts follow up for additional information as necessary, including consideration of reports with a fatal outcome, based on the completeness, severity, and clinical details provided in the report. Responses to follow-up requests for ADR reports are recorded and stored with the original report on our ADR database. The information is then passed downstream for use in signal detection and the identification of safety concerns.<\/p>
The data is available for its core purpose of assessment and signal detection, however, the systems were not designed to quantify follow-up metrics requested in this parliamentary question. As such it is not possible to automatically generate metrics on the proportion of follow-up requests sent. The MHRA has provided information on follow up rates under Freedom of Information, within the 20 day statutory timeframes based on manual review of reports, and is committed to publishing high level data on its website.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T17:44:25.937Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Yellow Card Scheme: Coronavirus"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many Yellow Cards for covid-19 vaccinations were (a) identified by the MHRA as being of special interest and (b) followed up by the MHRA in (i) 2021, (ii) 2022 and (iii) 2023.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"}
}
, "tablingMemberConstituency" : {"_value" : "Christchurch"}
, "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"}
], "uin" : "18344"}
, {"_about" : "http://data.parliament.uk/resources/1695797", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695797/answer", "answerText" : {"_value" : "
The increase in reported error in 2020/21 was due to the NHS Business Services Authority commencing the reporting of errors identified as part of their NHS Provider Assurance activity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T14:48:41.58Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Department of Health and Social Care: Fraud and Maladministration"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the report entitled Cross-Government Fraud Landscape: Annual Report 2022, published on 21 March 2023, what the basis is of the increase in detected error in her Department from £0.5m in 2019/20 to £43.2m in 2020/21.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4244", "label" : {"_value" : "Biography information for Jonathan Ashworth"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester South"}
, "tablingMemberPrinted" : [{"_value" : "Jonathan Ashworth"}
], "uin" : "18453"}
, {"_about" : "http://data.parliament.uk/resources/1695837", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695837/answer", "answerText" : {"_value" : "
The Gillick competence is a guideline used to determine whether children can provide informed consent based on their level of intelligence, knowledge, and competence. In schools, where requests for parental consent haven\u2019t been responded to, vaccinators may ask for the child\u2019s parents\u2019 contact details to seek oral consent over the phone. For young people, and children in secondary school settings who may be offered the measles, mumps and rubella vaccine alongside other school aged vaccinations, after every attempt to gain parental consent has been exhausted, the School Aged Immunisation Service team may make a clinical decision to give the vaccination using the Gillick competence framework. This allows a child to consent to their own treatment where appropriate, and when they are competent to do so.<\/p>
The Green Book Chapter two, Information for public health professionals on immunisation, provides guidance on seeking consent for vaccination, including the use of the Gillick competence. Obtaining consent to treatment and assessing the adequacy of the use of the Gillick competence in schools is the responsibility of each service provider.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T17:43:06.46Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Consent to Medical Treatment: Pupils"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the use of Gillick competence for vaccinations in schools.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "18534"}
, {"_about" : "http://data.parliament.uk/resources/1695838", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695838/answer", "answerText" : {"_value" : "
No assessment has been made of the adequacy of levels of parental choice and responsibility to decide the medical care their child receives. Those with parental responsibilities are entitled to give consent for medical treatment on behalf of their children. However, they are not entitled to inappropriate treatment for their children, or to refuse treatment which is in the child\u2019s best interests.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T17:52:24.24Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Health Services: Children"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the adequacy of levels of parental (a) choice and (b) responsibility to decide the medical care their child receives.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"}
}
, "tablingMemberConstituency" : {"_value" : "North East Hampshire"}
, "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"}
], "uin" : "18535"}
, {"_about" : "http://data.parliament.uk/resources/1695894", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695894/answer", "answerText" : {"_value" : "
The Government commissioned the Patient Safety Commissioner (PSC) to produce a report on redress for those affected by sodium valproate and pelvic mesh. We are grateful to the PSC and her team for completing this report, and our sympathies remain with those affected by sodium valproate and pelvic mesh. The Government is now carefully considering the PSC\u2019s recommendations, and will respond substantively in due course.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T10:34:57.187Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Surgical Mesh Implants: Compensation"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what her planned timetable is for making a decision on redress for people affected by mesh implants following the publication of The Hughes Report on 7 February 2024.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4616", "label" : {"_value" : "Biography information for Rosie Duffield"}
}
, "tablingMemberConstituency" : {"_value" : "Canterbury"}
, "tablingMemberPrinted" : [{"_value" : "Rosie Duffield"}
], "uin" : "18548"}
, {"_about" : "http://data.parliament.uk/resources/1695931", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695931/answer", "answerText" : {"_value" : "
Departmental officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including on access to medicines such as luspatercept (Reblozyl). The Department has had no discussions with Bristol Myers Squibb on this specific topic.<\/p>
Luspatercept has a licence in the United Kingdom for the treatment of adult patients with transfusion-dependent anaemia due to very low, and low and intermediate-risk myelodysplastic syndrome with ring sideroblasts, who had an unsatisfactory response to, or are ineligible for, erythropoietin-based therapy. The NICE had to terminate its appraisal of luspatercept for treating anaemia caused by myelodysplastic syndromes because the manufacturer did not provide an evidence submission. The NICE will review this decision if the company decides to make a submission.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-18", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-18T15:23:04.93Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Luspatercept: Licensing"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether she has had discussions with (a) NICE and (b) Bristol Myers Squibb on restarting the NICE appraisals process for luspatercept (Reblozyl).", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4769", "label" : {"_value" : "Biography information for Daisy Cooper"}
}
, "tablingMemberConstituency" : {"_value" : "St Albans"}
, "tablingMemberPrinted" : [{"_value" : "Daisy Cooper"}
], "uin" : "18616"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=1&answer.dateOfAnswer=2024-03-18", "page" : 0, "startIndex" : 1, "totalResults" : 41, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}